Work

Mucocutaneous Adverse Events Associated With Oral Sirolimus for the Treatment of Vascular Anomalies

Year: 2021

Type: article

Abstract: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that blocks signals from the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway, which coordinates cell proliferation and survival central to the development of vascular anomalies.1,2 Oral sirolimus is widely used to treat varied vascular anomalies and is associated with diverse adverse events (AEs), including leukopenia, gastrointestinal symptoms, infectious complications, and dyslipidemia.1,2 Limited data exist regarding dermatologic AEs in populations with vascular anomalies.

Source: JAMA Dermatology

DOI: 10.1001/jamadermatol.2020.5180